SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

A. Van Hazel, Guy; Heinemann, Volker; Sharma, Navesh; Findlay, Michael; Ricke, Jens; Peeters, Marc; Díaz Pérez, D; A. Robinson, Bridget; Strickland, Andrew; Ferguson, Tom; Rodríguez, Javier; Kröning, H.; Wolf, Ido; Ganju, Vinod; Walpole, Euan; Boucher, Éveline; Tichler, Thomas; Shacham‐Shmueli, Einat; Powell, Alex; Eliadis, Paul; Isaacs, Richard; Price, David; M Moeslein, Fred; Taı̈eb, Julien; Bower, G.; Gebski, Val; Van Buskirk, Mark; Cade, David; G. Thurston, Kenneth; Gibbs, Peter

doi:10.1200/jco.2015.66.1181

Public

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

Published in Journal of Clinical Oncology • Feb 22, 2016

Authors:

Guy A. Van Hazel

Volker Heinemann

Navesh Sharma

Abstract

PURPOSE: SIRFLOX was a randomized, multicenter trial designed to assess the efficacy and safety of adding selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres to standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)-based chemotherapy in patients with previously untr...

Subject

Medicine

Bevacizumab

Selective internal radiation therapy

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!